The NHS is set to significantly expand access to the weight loss injection Wegovy, specifically targeting tens of thousands of individuals who have survived heart attacks or strokes. This move follows updated guidance from the National Institute for Health and Care Excellence (NICE), which has approved the drug for this high-risk patient group to help prevent recurrent cardiovascular events.
New Eligibility Criteria for Life-Saving Treatment
NICE has widened eligibility for semaglutide, marketed as Wegovy, to include people who have experienced a heart attack, stroke, or serious circulation problems in their legs, provided they also carry excess weight. This decision comes after clinical trials demonstrated that the weekly appetite-suppressing injections could substantially reduce the risks of subsequent heart attacks and strokes.
Helen Knight, Director of Medicines Evaluation at NICE, emphasized the psychological impact on survivors, stating: "We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. Today's decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking."
Addressing a Major Public Health Challenge
Cardiovascular disease remains one of the leading causes of death in the United Kingdom, with approximately four million people living with coronary disease, strokes, or arterial disease. These individuals face a persistently high risk of further heart attacks and strokes despite existing treatments.
Health Minister Sharon Hodgson highlighted the transformative potential of this approach: "Weight loss drugs are proving to be a game changer in tackling obesity. Extending their use for people who also suffer from cardiovascular disease will be a life saver."
Scientific Evidence Behind the Decision
Clinical trials involving 17,604 participants showed that weekly semaglutide injections reduced the risk of major heart events by 20%, even before patients experienced significant weight loss. This suggests the drug may have direct beneficial effects on the heart and blood vessels beyond its appetite-suppressing properties.
Dr. Sonya Babu-Narayan, Clinical Director at the British Heart Foundation, explained: "So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today’s guidance will no doubt help save lives."
Implementation Challenges and Rollout Strategy
While the new guidance makes approximately 1.2 million additional people eligible for treatment, the NHS faces significant implementation challenges. Currently, only around 200,000 of the 3.4 million technically eligible patients receive the injections through the NHS, with the rollout being phased over several years.
The health service has been unable to offer the treatment to all eligible individuals due to capacity constraints in providing the necessary counselling support for lifestyle changes, coupled with global supply shortages of the medication.
Treatment Protocol and Patient Criteria
According to the updated NICE guidance, patients with a body mass index (BMI) of 27 or higher who have previously experienced cardiovascular events can receive semaglutide. The treatment should be used alongside other medications like statins, combined with a reduced-calorie diet and increased physical activity.
Professor Riyaz Patel, consultant Cardiologist at Barts Health NHS Trust, noted the broader implications: "This is a very important development. This risk comes with significant personal cost but also financial impacts on the NHS."
Industry and Professional Response
Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement: "Although more details are needed, this is a very significant announcement and could be game changing in reducing the risk of heart attacks and strokes, one of the leading causes of death in the UK."
The expansion represents a strategic shift in how weight loss medications are viewed within the healthcare system, transitioning from purely obesity management tools to important cardiovascular preventive medicines that could save thousands of lives annually.
